NCT00020748View on ClinicalTrials.gov

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2000

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

epirubicin hydrochloride

DRUG

irinotecan hydrochloride

Trial Locations (1)

20007

Lombardi Cancer Center at Georgetown University Medical Center, Washington D.C.

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Georgetown University

OTHER

NCT00020748 - Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter